Core Viewpoint - Changjiang Life Sciences (00775) saw a significant stock increase of 8.6%, reaching HKD 1.01, with a trading volume of HKD 23.28 million, following the presentation of its cancer immunotherapy research at the SITC 2025 conference [1] Group 1: Company Developments - Changjiang Life Sciences showcased its research advancements in cancer vaccines targeting TROP2, PRAME, and PD-L1 at the SITC 2025 conference [1] - The company’s Vice President and Chief Scientific Officer, Dr. Du Jianming, expressed optimism about the progress of the cancer vaccine candidates targeting TROP2 and PRAME/PD-L1, indicating a potential acceleration in the development of effective therapeutic cancer vaccines [1] - The current objective for the company is to advance these vaccine candidates to the clinical trial stage [1]
长江生命科技再涨超8% 公司展示抑制肿瘤生长研发成果 疫苗研究进程有望加速